Indrani Nayak, Rosalba Biondo, William C Stewart, Rebecca J Fulton, Nina Möker, Congcong Zhang, Salim I Khakoo, Jayajit Das
{"title":"Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.","authors":"Indrani Nayak, Rosalba Biondo, William C Stewart, Rebecca J Fulton, Nina Möker, Congcong Zhang, Salim I Khakoo, Jayajit Das","doi":"10.1111/imcb.12848","DOIUrl":null,"url":null,"abstract":"<p><p>Natural killer (NK) cells are emerging agents for cancer therapy. Several different cytokines are used to generate NK cells for adoptive immunotherapy including interleukin (IL)-2, IL-12, IL-15 and IL-18 in solution, and membrane-bound IL-21. These cytokines drive NK cell activation through the integration of signal transducers and activators of transcription (STAT) and nuclear factor-kappa B (NF-κB) pathways, which overlap and synergize, making it challenging to predict optimal cytokine combinations for both proliferation and cytotoxicity. We integrated functional assays for NK cells cultured in a variety of cytokine combinations with mathematical modeling using feature selection and mechanistic regression models. Our regression model successfully predicts NK cell proliferation for different cytokine combinations and indicates synergy of activated STATs and NF-κB transcription factors between priming and post-priming phases. The use of IL-21 in solution in the priming of NK cell culture resulted in an improved NK cell proliferation, without compromising cytotoxicity potential or interferon gamma secretion against hepatocellular carcinoma cell lines. Our work provides an integrative framework for interrogating NK cell proliferation and activation for cancer immunotherapy.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology & Cell Biology","FirstCategoryId":"2","ListUrlMain":"https://doi.org/10.1111/imcb.12848","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
自然杀伤(NK)细胞是新兴的癌症治疗药物。有几种不同的细胞因子可用于产生NK细胞,用于采纳性免疫疗法,包括溶液中的白细胞介素(IL)-2、IL-12、IL-15和IL-18,以及膜结合的IL-21。这些细胞因子通过信号转导和转录激活因子(STAT)与核因子-卡巴B(NF-κB)途径的整合来驱动NK细胞的活化,这两种途径会重叠并产生协同作用,因此预测细胞因子的最佳增殖和细胞毒性组合具有挑战性。我们将多种细胞因子组合培养的 NK 细胞的功能测试与使用特征选择和机理回归模型的数学建模相结合。我们的回归模型成功预测了不同细胞因子组合的 NK 细胞增殖情况,并显示了激活的 STAT 和 NF-κB 转录因子在引物阶段和引物后阶段之间的协同作用。在 NK 细胞培养的启动阶段使用溶液中的 IL-21 可改善 NK 细胞的增殖,同时不影响细胞毒性潜力或针对肝细胞癌细胞系的伽马干扰素分泌。我们的工作提供了一个综合框架,可用于研究癌症免疫疗法中的 NK 细胞增殖和活化。
Modeling the response to interleukin-21 to inform natural killer cell immunotherapy.
Natural killer (NK) cells are emerging agents for cancer therapy. Several different cytokines are used to generate NK cells for adoptive immunotherapy including interleukin (IL)-2, IL-12, IL-15 and IL-18 in solution, and membrane-bound IL-21. These cytokines drive NK cell activation through the integration of signal transducers and activators of transcription (STAT) and nuclear factor-kappa B (NF-κB) pathways, which overlap and synergize, making it challenging to predict optimal cytokine combinations for both proliferation and cytotoxicity. We integrated functional assays for NK cells cultured in a variety of cytokine combinations with mathematical modeling using feature selection and mechanistic regression models. Our regression model successfully predicts NK cell proliferation for different cytokine combinations and indicates synergy of activated STATs and NF-κB transcription factors between priming and post-priming phases. The use of IL-21 in solution in the priming of NK cell culture resulted in an improved NK cell proliferation, without compromising cytotoxicity potential or interferon gamma secretion against hepatocellular carcinoma cell lines. Our work provides an integrative framework for interrogating NK cell proliferation and activation for cancer immunotherapy.
期刊介绍:
The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.